###begin article-title 0
Skeletal Muscle-Specific Deletion of Lipoprotein Lipase Enhances Insulin Signaling in Skeletal Muscle but Causes Insulin Resistance in Liver and Other Tissues
###end article-title 0
###begin p 1
###xml 39 61 39 61 <email xmlns:xlink="http://www.w3.org/1999/xlink">robert.eckel@uchsc.edu</email>
Corresponding author: Robert H. Eckel, robert.eckel@uchsc.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
OBJECTIVE-Skeletal muscle-specific LPL knockout mouse (SMLPL-/-) were created to study the systemic impact of reduced lipoprotein lipid delivery in skeletal muscle on insulin sensitivity, body weight, and composition.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 245 248 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-Tissue-specific insulin sensitivity was assessed using a hyperinsulinemic-euglycemic clamp and 2-deoxyglucose uptake. Gene expression and insulin-signaling molecules were compared in skeletal muscle and liver of SMLPL-/- and control mice.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 134 137 134 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 278 281 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 520 523 520 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 672 675 672 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 905 908 905 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
RESULTS-Nine-week-old SMLPL-/- mice showed no differences in body weight, fat mass, or whole-body insulin sensitivity, but older SMLPL-/- mice had greater weight gain and whole-body insulin resistance. High-fat diet feeding accelerated the development of obesity. In young SMLPL-/- mice, insulin-stimulated glucose uptake was increased 58% in the skeletal muscle, but was reduced in white adipose tissue (WAT) and heart. Insulin action was also diminished in liver: 40% suppression of hepatic glucose production in SMLPL-/- vs. 90% in control mice. Skeletal muscle triglyceride was 38% lower, and insulin-stimulated phosphorylated Akt (Ser473) was twofold greater in SMLPL-/- mice without changes in IRS-1 tyrosine phosphorylation and phosphatidylinositol 3-kinase activity. Hepatic triglyceride and liver X receptor, carbohydrate response element-binding protein, and PEPCK mRNAs were unaffected in SMLPL-/- mice, but peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha and interleukin-1beta mRNAs were higher, and stearoyl-coenzyme A desaturase-1 and PPARgamma mRNAs were reduced.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-LPL deletion in skeletal muscle reduces lipid storage and increases insulin signaling in skeletal muscle without changes in body composition. Moreover, lack of LPL in skeletal muscle results in insulin resistance in other key metabolic tissues and ultimately leads to obesity and systemic insulin resistance.
###end p 6
###begin p 7
Published ahead of print at  on 24 October 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 32 34 32 34 <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" vol="58" page="16" id="N0x4337730N0x39a5910" xlink:href="19114724" ext-link-type="pubmed">16</related-article>
See accompanying commentary, p. 16.
###end p 9
###begin p 10
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 119 129 <span type="species:ncbi:111938">gatekeeper</span>
Lipoprotein lipase (LPL) (European Commission no. 3.1.1.34) is a key enzyme in lipid metabolism and is described as a "gatekeeper" for its role in partitioning lipoprotein-derived free fatty acids (FFAs) between tissues. Once hydrolyzed, the lipoprotein-derived FFAs are available for uptake and use by extrahepatic tissues for either storage or oxidation. LPL is most abundant in heart, adipose tissue, and skeletal muscle (1,2). The importance of LPL in fuel partitioning and utilization is underscored by observations that tissue-specific perturbations in LPL activity result in dramatic shifts in body composition and lipid and glucose metabolism (3), particularly in heart and skeletal muscle.
###end p 10
###begin p 11
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
We and others previously showed that mice with muscle-specific lipoprotein lipase overexpression are insulin resistant (4,5). Insulin resistance developed selectively in muscle, while insulin sensitivity in the liver was not affected. Overexpression of LPL in the skeletal muscle also led to excessive intramyocellular lipid deposition, suggestive of the relationship between lipid storage and insulin sensitivity.
###end p 11
###begin p 12
###xml 232 235 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
To further investigate the systemic impact of skeletal muscle LPL (SMLPL) on lipoprotein-derived fatty acid partitioning between tissues and insulin sensitivity, we generated skeletal muscle-specific LPL knockout mice, denoted SMLPL-/-. We hypothesized that SMLPL is an important interface through which lipid-derived signals are integrated to regulate insulin signaling and that SMLPL deletion would perturb the balance of fuel utilization not only in skeletal muscle but also in other insulin-sensitive tissues.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
Animals.
###end title 14
###begin p 15
###xml 200 203 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 365 368 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 518 521 518 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 613 616 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 247 262 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 301 316 <span type="species:ncbi:10090">transgenic mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
Studies were conducted in accordance to protocols approved by institutional animal care and use committees (University of Colorado Denver Anschutz Medical Campus, Pennsylvania State University). SMLPL-/- mice were generated by the cre-lox system. Transgenic mice with floxed LPL (6) were crossed with transgenic mice in which skeletal muscle-specific expression of cre recombinase was driven by the myosin light chain 1f gene promoter (7). Offspring were then crossed with each other to produce mice with at least one cre allele and either two floxed LPL alleles or two wild-type LPL alleles. The presence of the cre transgene and either wild-type or floxed LPL was verified by PCR.
###end p 15
###begin p 16
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 286 289 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
Male 9- to 11-week-old (young) or 8- to 10-month-old (old) SMLPL-/- and wild-type littermate control mice were housed at approximately20degreesC on a 12:12 h light: dark photoperiod and provided standard rodent food and water ad libitum. For high-fat (HF) diet feeding, 6-week-old SMLPL-/- and control mice were put on an HF diet (Research Diet, 45% fat) and a 10% low-fat (LF) diet matched for other nutrient content for 6 weeks. Unless specified, mice were anesthetized with intraperitoneal administration of Avertin (250 mg/kg 2,2,2-tribromoethanol) after a 4-h fast.
###end p 16
###begin title 17
Glucose and insulin tolerance tests.
###end title 17
###begin p 18
Glucose and insulin tolerance tests were performed by bolus intraperitoneal injection of glucose (1 g/kg) or insulin (0.75 units/kg), respectively. Blood glucose was measured from the tail using a glucometer (OneTouch Ultra, Lifescan) at baseline (0) and 10, 20, 30, 45, 60, and 90 min after injection.
###end p 18
###begin title 19
LPL activity assay.
###end title 19
###begin p 20
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
Tissues were dissected and assayed immediately. Heparin-releasable LPL activity was measured in heart, white adipose tissue (WAT), red skeletal muscle (soleus and red gastrocnemius), and white skeletal muscle (white gastrocnemius) as previously described (8). LPL activity was expressed as nanomoles of FFA per minute per gram of tissue.
###end p 20
###begin title 21
Measurement of body composition, plasma profiles, and tissue lipid content.
###end title 21
###begin p 22
###xml 950 951 935 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1085 1087 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1088 1090 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1163 1164 1148 1149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1240 1242 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1343 1345 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1346 1348 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Body composition was measured on anesthetized mice by dual-energy X-ray absorptiometry using a mouse densitometer (PIXImus2; Lunar, Madison, WI). Blood was collected by cardiac puncture, and plasma was stored at -80degreesC until further analysis. Plasma glucose was measured using the Analox GM7 (Analox Instruments, Lunenburg, MA), FFAs were measured using enzymatic colorimetric assays (Wako Chemicals, Richmond, VA), and insulin was measured using a radioimmunoassay kit (Linco Research, St. Charles, MO). Plasma cholesterol was measured on an Olympus AU400e chemistry analyzer (Olympus America, Center Valley, PA). Plasma leptin, adiponectin, interleukin (IL)-1beta, and IL-6 were measured using specific enzyme-linked immunoassay (ELISA) kits (Alpco Diagnostics, Salem, NH). Red skeletal muscle, liver, and heart tissue were excised, flash-frozen, and stored at -80degreesC until triglyceride (TG) content was measured as previously described (9). Long-chain fatty acyl-coenzyme A (LC acyl-CoA) was extracted and purified from skeletal muscle using methods described previously (10,11). After purification, LC acyl-CoA fractions were dissolved in methanol/H2O (1:1; vol/vol) and subjected to liquid chromatography/tandem MS analysis (12). Diacylglycerol (DAG) and ceramide extraction and analysis were performed as described previously (12,13). Total LC acyl-CoA, DAG, and ceramides are expressed as the sum of individual species.
###end p 22
###begin title 23
Indirect calorimetry measurements.
###end title 23
###begin p 24
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
An open-ended indirect calorimetry system was used to measure oxygen consumption O2 and CO2 production in mice for the calculation of metabolic rate and respiratory quotient (14). Animals were placed in metabolic chambers for measurements taken over at least 2 days with free access to food and water.
###end p 24
###begin title 25
Hyperinsulinemic-euglycemic clamps.
###end title 25
###begin p 26
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 573 576 561 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 740 742 728 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 748 750 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1108 1109 1095 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1319 1320 1304 1305 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 1324 1326 1309 1311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 1340 1342 1325 1327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 43 48 <span type="species:ncbi:10090">Mouse</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 1450 1454 <span type="species:ncbi:10090">mice</span>
This study was performed at the Penn State Mouse Metabolic Phenotyping Center, and the procedures were approved by the Pennsylvania State University Institutional Animal Care and Use Committee. At 4-5 days before clamp experiments, mice were anesthetized, and an indwelling catheter was inserted in the right internal jugular vein (15). On the day of the clamp experiment, a three-way connector was attached to the catheter to intravenously deliver solutions. After an overnight fast (approximately15 h), a 2-h hyperinsulinemic-euglycemic clamp was conducted in awake SMLPL-/- mice and wild-type littermates with a primed (150 mU/kg body wt) and continuous infusion of insulin (Humulin; Eli Lilly, Indianapolis, IN) at a rate of 2.5 mU . kg-1 . min-1 to raise plasma insulin within a physiological range. Blood samples (20 mul) were collected at 20-min intervals for measurement of plasma glucose concentration, and 20% glucose was infused at variable rates to maintain glucose at basal concentrations. Basal and insulin-stimulated whole-body glucose turnover were estimated with a continuous infusion of [3-3H]glucose (PerkinElmer, Boston, MA) for 2 h before the clamps (0.05 muCi/min) and throughout the clamps (0.1 muCi/min), respectively. To estimate insulin-stimulated glucose uptake in individual organs, 2-deoxy-d-[1-14C]glucose (2-[14C]-DG) was administered as a bolus (10 muCi) at 75 min after the start of clamps. At the end of the clamps, mice were anesthetized, and tissues were taken for biochemical analysis.
###end p 26
###begin title 27
In vitro 2-deoxyglucose uptake in muscle.
###end title 27
###begin p 28
###xml 152 153 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 160 161 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 446 448 433 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 475 476 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 773 775 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 929 930 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1058 1060 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
To measure 2-deoxyglucose (2-DG) uptake, paired soleus were dissected from anesthetized mice and incubated at 37degreesC for 30 min in oxygenated (95% O2, 5% CO2) flasks of Krebs-Henseleit buffer (KHB) containing the following, with or without 50 muU/ml insulin: 0.1% BSA, 2 mmol/l Na-pyruvate, and 6 mmol/l mannitol. After 30 min, muscles were transferred to a second flask and incubated at 37degreesC for 20 min in KHB plus 0.1% BSA, 9 mmol/l [14C]-mannitol, and 1 mmol/l [3H]-2-DG (0.053 and 3 mCi/mmol, respectively; Perkin Elmer, Boston, MA) with the same insulin concentration. After 20 min, muscles were blotted on ice-cold filter paper, trimmed, and freeze-clamped and then stored (-80degreesC). Frozen muscles were weighed and homogenized as previously described (16). The homogenate was transferred to microfuge tubes and solubilized (1-2 h, 4degreesC) with end-over-end rotation. The homogenate was centrifuged (12,000g, 12 min, 4degreesC) and used immediately for 2-DG uptake measurement. 2-DG uptake rate was calculated as previously described (17).
###end p 28
###begin title 29
Insulin signaling.
###end title 29
###begin p 30
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
Basal and insulin-stimulated red skeletal muscle, WAT, and insulin-stimulated liver were collected from young anesthetized mice as described previously (9). After a 10 units/kg dose of insulin (Humulin), administered via the inferior vena cava, tissues were flash-frozen in liquid nitrogen and stored at -80degreesC until analysis. Basal liver tissues were collected from a different set of mice that did not receive insulin.
###end p 30
###begin p 31
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
For Western blot analysis, tissues were homogenized in cell lysis buffer (9). A total of 50 mug protein was electrophoresed on 8% or 10% precast SDS-PAGE gels and transferred onto a PVDF membrane. Blots were probed with antibodies for IR and IRS-1 phospho-tyrosine (P-Tyr-100), phospho-Akt (S473), and phosphor-Akt (T308) (all from Cell Signaling) first and then stripped and probed again with antibodies for total IR (Santa Cruz), IRS-1 (Upstate), Akt, PTEN, and SHIP2 (Cell Signaling). Results were detected by chemiluminescence (ECL; Amersham Biosciences, Piscataway, NJ) and visualized on X-ray films and analyzed using an HC Precision Scan Pro and Bio-Rad Quantity One Analysis Software. An internal standard (wild-type mouse homogenate) was used to normalize results and to control for blot-to-blot variation.
###end p 31
###begin p 32
###xml 173 175 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
The level of IRS-1-associated PI 3-kinase activity was determined in muscle extracts after immunoprecipitation with IRS-1 antibody/agarose conjugate overnight at 4degreesC (18).
###end p 32
###begin title 33
Quantitative real-time PCR.
###end title 33
###begin p 34
###xml 1198 1201 1168 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18a">18a</xref>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Red skeletal muscle, white skeletal muscle, liver, WAT, and heart were collected from young anesthetized mice, flash-frozen, and stored at -80degreesC until processing. Total RNA was extracted from homogenized tissue using both TRIZOL reagent (Invitrogen) and RNeasy Mini Kit (Qiagen). One-step RT-PCR was performed using 50 ng total RNA with iScript One-Step RT-PCR Kit for Probes (Bio-Rad, Hercules, CA) and TaqMan Gene Expression Assays (ABI, Foster City, CA). For three internal reference genes, one-step RT-PCR was performed using an iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad). Reactions were run in duplicate on an iQ5 Real-Time PCR Detection System (Bio-Rad) along with no-template controls per gene. The cycling conditions comprised 10-min cDNA synthesis at 50degreesC, 5-min reverse transcriptase inactivation at 95degreesC, and 45 cycles at 95degreesC for 10 s and 60degreesC for 30 s. RNA expression data were normalized to levels of ubiquitin C (Ubc) RNA, hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1) RNA, and actin beta (Actb) RNA using the comparative threshold cycle method. Ubc, Hprt1, and Actb primer sets, as described in the study by Vandesompele et al. (18a), were as follows: Ubc forward primer 5'-AGGTCAAACAGGAAGACAGACGTA-3', Ubc reverse primer 5'-TCACACCCAAGAACAAGCACA-3'; Hprt1 forward primer 5'-AGTGTTGGATACAGGCCAGAC-3', Hprt1 reverse primer 5'-CGTGATTCAAATCCCTGAAGT-3'; and Actb forward primer 5'-ATGCTCCCCGGGCTGTAT-3', Actb reverse primer 5'-CATAGGAGTCCTTCTGACCCATTC-3'.
###end p 34
###begin title 35
Statistical analysis.
###end title 35
###begin p 36
###xml 43 44 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 104 105 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are presented as means +/- SE. The t tests were performed using SigmaStat 2.03 (San Rafel, CA). P < 0.05 was considered significant.
###end p 36
###begin title 37
RESULTS
###end title 37
###begin title 38
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
Skeletal muscle-specific LPL ablation (SMLPL-/-).
###end title 38
###begin p 39
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 206 213 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 362 369 362 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 420 423 420 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
In 9- to 11-week-old SMLPL-/- mice, RT-PCR showed a 83% reduction (P < 0.001) in LPL mRNA expression in the red skeletal muscle, with only 50% reduction in white skeletal muscle and no change in the heart (Fig. 1A). Skeletal muscle LPL activity was decreased by 72% (P < 0.001) in the predominantly red muscle fibers of the soleus and red gastrocnemius muscles (Fig. 1B). White muscle LPL activity was 22% lower in SMLPL-/- mice and was not statistically significant (P = 0.131). LPL activities in heart and WAT were not affected.
###end p 39
###begin title 40
Body composition, plasma metabolite profiles, and energy balance.
###end title 40
###begin p 41
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 125 135 125 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 137 144 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 184 187 184 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 260 267 260 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 269 280 269 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
The reduction of LPL activity in skeletal muscle did not alter body composition of 9- to 11-week-old SMLPL-/- mice (Fig. 1C, left panel; Table 1). However, at 8-10 months of age, SMLPL-/- mice were heavier than controls with most of the extra weight fat mass (Fig. 1C, right panel).
###end p 41
###begin p 42
###xml 129 136 129 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 334 337 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 344 351 344 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 470 477 467 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
Whole-body metabolic rate, respiratory quotient, and energy intake were also not different between the two groups of young mice (Table 1). After a 4-h fast, plasma glucose, insulin, total and lipoprotein cholesterol, and FFA levels were similar between young SMLPL-/- and control mice, with a trend for higher TGs (P = 0.074) in SMLPL-/- mice (Table 2). Plasma leptin, adiponectin, IL-1beta, and IL-6 also were not different between the two groups at 9-11 weeks of age (Table 2).
###end p 42
###begin p 43
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 146 153 146 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
To determine whether high-fat feeding might accelerate the obesity phenotype, 6-week-old SMLPL-/- mice were subjected to the HF diet for 6 weeks (Fig. 1D). After 4 weeks on the HF diet, SMLPL-/- mice were heavier than control mice (P = 0.031 for 4 weeks; P = 0.015 for 6 weeks).
###end p 43
###begin title 44
Glucose tolerance and insulin tolerance tests.
###end title 44
###begin p 45
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 96 109 96 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 176 183 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 208 211 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 287 294 287 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
Although blood glucose, insulin, and insulin tolerance were not altered in chow-fed young mice (Fig. 2A and B), SMLPL-/- mice developed glucose intolerance by 6 months of age (Fig. 2C). Moreover, HF-fed SMLPL-/- mice had elevated plasma glucose levels compared with HF-fed control mice (Fig. 2D).
###end p 45
###begin title 46
Whole-body insulin sensitivity and tissue-specific glucose metabolism.
###end title 46
###begin p 47
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 155 157 151 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 163 165 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 187 188 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 181 188 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 190 194 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 230 233 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 376 378 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 384 386 378 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 447 449 439 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 455 457 447 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 480 481 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 498 499 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 492 499 484 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 501 506 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 530 533 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 584 585 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 578 585 570 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
Insulin sensitivity in 9- to 11-week-old mice was comparable between SMLPL-/- and control mice with glucose infusion rates of 39 +/- 4 and 44 +/- 4 mg . kg-1 . min-1, respectively (Fig. 3A, left). Of great interest, however, SMLPL-/- mice displayed a reduced capacity of insulin to suppress hepatic glucose production with only 39 +/- 8% suppression (from 19.1 to 11.1 mg . kg-1 . min-1) compared to 91 +/- 8% suppression (from 20.5 to 0.4 mg . kg-1 . min-1) in the control mice (P = 0.001) (Fig. 3A, right). At 8-10 months, SMLPL-/- mice developed systemic insulin resistance (Fig. 3B).
###end p 47
###begin p 48
###xml 115 118 115 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 159 161 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 167 169 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 171 172 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 244 246 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 252 254 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 256 257 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 318 320 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 326 328 314 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 330 331 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 348 349 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 342 349 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 437 440 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 484 486 468 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 492 494 476 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 496 497 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
More surprisingly, 2-DG uptake measured at the end of the clamp was increased in skeletal muscle of the young SMLPL-/- mice (539 +/- 48 vs. 341 +/- 20 nmol . g-1 . min-1, P = 0.003) but was greatly reduced in WAT (11 +/- 3 vs. 51 +/- 9 nmol . g-1 . min-1, P = 0.003) and heart (1,798 +/- 359 vs. 3,257 +/- 223 nmol . g-1 . min-1, P = 0.006) (Fig. 3C). A trend for reduced glucose uptake was also observed in brown adipose tissue of SMLPL-/- mice (582 +/- 90 vs. 1,552 +/- 424 nmol . g-1 . min-1, P = 0.072).
###end p 48
###begin p 49
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 120 127 120 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 217 220 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 417 420 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
The maximal glucose transport activity in isolated soleus muscle was measured for both young SMLPL-/- and control mice (Fig. 3D). In control mice, glucose transport was increased 40% upon insulin stimulation. In SMLPL-/- mice, basal glucose transport was increased 25% compared with control mice, and it was further increased 80% upon insulin stimulation (P = 0.01 vs. control). Thus, skeletal muscle from young SMLPL-/- mice displayed a higher basal glucose transport activity and was more responsive to insulin both in vivo and ex vivo.
###end p 49
###begin p 50
###xml 80 84 <span type="species:ncbi:10090">mice</span>
These findings indicated that skeletal muscle-specific deletion of LPL in young mice increased insulin sensitivity selectively in skeletal muscle but caused insulin resistance in liver, heart, and adipose tissues, suggesting that reciprocal changes in insulin action in different tissues might be responsible for the lack of changes in whole-body insulin sensitivity.
###end p 50
###begin title 51
Skeletal muscle TG content reduced with no change in other lipid metabolites.
###end title 51
###begin p 52
###xml 123 126 123 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 194 201 194 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 209 212 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 418 421 418 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 440 447 440 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 497 500 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 513 514 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 507 514 507 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
To understand whether changes in cellular and circulating lipids might underlie the changes in insulin sensitivity in SMLPL-/- mice, we measured TG content in skeletal muscle, liver, and heart (Fig. 4A). SMLPL-/- mice showed a 40% reduction (P = 0.045) in skeletal muscle TG, with no difference in liver TG. Yet there were no differences in intramuscular total LC acyl-CoA, total DAG, or total ceramide levels in SMLPL-/- and control mice (Fig. 4B). Heart TG was not different (P = 0.126) in SMLPL-/- mice (Fig. 4A).
###end p 52
###begin title 53
Increased insulin signaling in skeletal muscle.
###end title 53
###begin p 54
###xml 69 72 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 379 388 379 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A&#8211;C</italic></xref>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 529 530 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 523 530 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 562 565 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 695 698 695 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 780 781 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 874 877 874 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 902 903 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 896 903 896 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 1027 1030 1027 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1043 1044 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1037 1044 1037 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 1031 1035 <span type="species:ncbi:10090">mice</span>
Because glucose uptake in the skeletal muscle was higher in the SMLPL-/- mice during the hyperinsulinemic clamp, we investigated whether this was due to changes in the insulin-signaling cascade. Surprisingly, there were no differences in the total levels of IR, IRS-1, Akt, insulin-stimulated tyrosine phosphorylation of the insulin receptor or IRS-1, or PI 3-kinase activation (Fig. 5A-C). However, we observed a nearly twofold increase in net insulin-stimulated Ser473 Akt activation (P < 0.01) upon insulin stimulation (Fig. 5D) in the red muscle of the SMLPL-/- mice. Full activation of Akt also requires the phosphorylation of threonine 308 of the activation loop in Akt by PDK1 (19). SMLPL-/- mice showed a 40% increase in Thr308 Akt phosphorylation under basal conditions (P = 0.05), while insulin induced a similar 50% increase of Thr308 Akt phosphorylation in SMLPL-/- and control mice (Fig. 5E). The levels of two lipid phosphatases known to modify Akt phosphorylation (PTEN and SHIP2) (20,21) were unchanged in SMLPL-/- mice (Fig. 5F).
###end p 54
###begin p 55
###xml 302 306 <span type="species:ncbi:10090">mice</span>
Examination of the insulin-signaling cascade in liver and WAT showed no differential activation (data not shown). Specifically, and unlike the response to insulin in red skeletal muscle, the level of insulin-stimulated Akt phosphorylation was not different in the liver or the WAT of the two groups of mice.
###end p 55
###begin title 56
Gene regulation in skeletal muscle and liver.
###end title 56
###begin p 57
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 195 202 195 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 625 628 605 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 635 636 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
Quantitative real-time PCR (qRT-PCR) was performed to examine whether the loss of SMLPL affected important genes involved in lipid, glucose, and fatty acid metabolism in the skeletal red muscle (Fig. 6A). In eight representative genes examined, the mRNA expression levels of peroxisome proliferator-activated receptor (PPAR)alpha, PPARgamma, tumor necrosis factor (TNF)-alpha, carnitine palmitoyl transferase-2, CD36, acetyl-coenzyme A carboxylase 2, and fibroblast growth factor 21 were not altered. Interestingly, the mRNA level of PPARgamma coactivator (PGC)-1alpha was increased by 60% in the skeletal red muscle of SMLPL-/- mice (P = 0.01).
###end p 57
###begin p 58
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 286 287 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 346 347 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 365 368 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 519 522 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 529 530 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 543 544 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
Similar qRT-PCR was performed on the liver of SMLPL-/- and control mice. A total of 13 representative genes were compared (Fig. 6B), and none of the gluconeogenic genes examined (PEPCK and glucose-6-phosphatase) showed differential expression. IL-1beta expression was increased by 64% (P = 0.034), and PGC-1alpha expression was increased by 73% (P = 0.005) in SMLPL-/- liver. On the other hand, the hepatic gene expression levels for SCD-1 and PPARgamma mRNA were significantly lower (69 and 57%, respectively) in SMLPL-/- mice (P = 0.049 and P = 0.001, respectively).
###end p 58
###begin p 59
A comparison of 10 representative genes in WAT showed a trend for an increase in genes related to inflammatory pathways: CD68, IL-1beta, IL-6, and TNF-alpha; however, these changes were not statistically significant (data not shown).
###end p 59
###begin title 60
DISCUSSION
###end title 60
###begin p 61
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 622 625 622 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
Lipid partitioning between tissues is important to insulin action, energy balance, and the regulation of body weight and composition. The normal physiology of lipid and lipoprotein fuel partitioning is controlled by the transport and uptake of adipose tissue-derived FFA and lipoprotein-derived TG fatty acids. Tissue-specific changes in the regulation of LPL in obese subjects may play an important role in nutrient partitioning when energy intake exceeds energy expenditure (22-26). Thus, the ability to selectively modify LPL in skeletal muscle and/or adipose tissue may influence body weight and composition. The SMLPL-/- mice were created to provide a model to study how reduced lipid partitioning to skeletal muscle influences insulin-sensitive tissues and the potential role in regulating body weight, body composition, and whole-body insulin sensitivity.
###end p 61
###begin p 62
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 244 247 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
SMLPL-/- mice show a transition of phenotypes between young and old animals. At a young (9-11 weeks) age, body weight and percent fat were unchanged compared with WT controls. With aging, both body weight and percent fat were increased in SMLPL-/- and systemic insulin resistance developed. The transition of the phenotype was accelerated by feeding the young SMLPL-/- mice with HF diets. Such information suggests an increased propensity that lipid storage develops and that accompanies lower lipid deposition in skeletal muscle.
###end p 62
###begin p 63
###xml 540 543 540 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
The deletion of LPL in skeletal muscle results in two distinct patterns of clinical and biochemical abnormalities in young mice. The first is an increase in insulin sensitivity in skeletal muscle. The second is the decrease of insulin sensitivity in liver and other tissues. The present data suggest that skeletal muscle, and LPL in particular, acts as an important buffer against excess lipid storage but cannot protect against the ultimate development of obesity or insulin resistance. Despite no change in body composition in young SMLPL-/- mice or whole-body glucose disposal during the hyperinsulinemic clamp, closer inspection of individual tissues revealed that insulin-stimulated 2-DG uptake was significantly greater in skeletal muscle, whereas other insulin-sensitive tissues (WAT, heart) showed remarkable reductions in insulin-stimulated glucose uptake.
###end p 63
###begin p 64
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 452 455 452 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
The increase in insulin-stimulated glucose uptake in skeletal muscle of young SMLPL-/- mice was associated with reduced TG accumulation in skeletal muscle and increased basal and insulin-stimulated Akt phosphorylation. Interestingly, there were no differences in the accumulation of other metabolic intermediates such as LC acyl-CoAs, ceramides, and DAG in skeletal muscle. Unexpectedly, the significant effect on increased Akt phosphorylation in SMLPL-/- mice was not associated with greater IRS-1 or PI 3-kinase activity. This suggests that LPL may play a role in regulating other lipid-derived factors that affect Akt phosphorylation in skeletal muscle.
###end p 64
###begin p 65
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 506 509 506 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 923 926 923 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1235 1238 1235 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
###xml 927 931 <span type="species:ncbi:10090">mice</span>
###xml 1239 1243 <span type="species:ncbi:10090">mice</span>
Because the total PTEN and SHIP2 levels were not different in SMLPL-/- versus control mice, it is unlikely that these two negative regulators of Akt activity contribute to the increased Akt phosphorylation we observed in SMLPL-/- mice. Increased Akt phosphorylation at Ser473 has been associated with the mammalian target of rapamycin(mTOR)-rictor complex (27,28). Because there was no change in the Ser-IRS-1 phosphorylation (an mTOR target), it suggests that there may be other regulators of Akt in SMLPL-/- mice. For example, phosphorylation of Akt at Thr308 and Ser473 can be inhibited by direct binding of two different proteins: carboxyl-terminal modulator protein or TRB3 (29,30). Also, a pH domain leucine-rich repeat protein phosphatase (PHLPP) has also been shown to specifically dephosphorylate Ser-473 and inactivate Akt (31). Interestingly, insulin-stimulated Akt Thr308 phosphorylation was unaffected in SMLPL-/- mice, suggesting that there might be different combination of pathways affecting Akt activation. In subsequent studies, it will be important to identify which of these possible mediators might serve as the link between reduced LPL-mediated lipid uptake and deposition and enhanced Akt activation in our SMLPL-/- mice.
###end p 65
###begin p 66
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 169 172 169 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 339 342 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 508 511 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
Increased insulin-stimulated glucose uptake and lower TG in skeletal muscle of young SMLPL-/- mice also suggest that the loss of LPL activity in skeletal muscle in SMLPL-/- mice creates a preference for glucose rather than TG-rich lipoproteins for fuel. Because plasma lipoprotein TG and liver TG were not statistically different for SMLPL-/- and control mice, more TG-rich lipoprotein TG may be processed in liver, WAT, or heart. Noting that LPL activity in WAT tissue was only marginally increased in SMLPL-/- mice and the fat mass remained the same as control mice, WAT tissue could be compensating for the loss of LPL in skeletal muscle by enhancing lipoprotein-dependent lipid uptake and turnover. However, at 9-11 weeks, there was no increase in TG storage in the heart, an important organ in the metabolism of TG-rich lipoproteins. It is very likely at this stage of phenotypic development that the heart increased fatty acid oxidation in response to the reduced lipid partitioning to skeletal muscle.
###end p 66
###begin p 67
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 255 258 255 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 320 323 320 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 484 487 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 684 687 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
Despite increased skeletal muscle insulin sensitivity, SMLPL-/- mice also displayed hepatic insulin resistance, as indicated by the reduced capacity to suppress hepatic glucose production upon insulin stimulation. However, TG content in the liver of SMLPL-/- mice was not increased. Gene expression in the liver of SMLPL-/- mice was mostly unchanged, whereas PGC-1alpha and IL-1beta expression was modestly increased, and PPAR-gamma and SCD-1 mRNA levels reduced in the liver of SMLPL-/- mice. The increase in IL-1beta expression suggests a possible role of this cytokine in mediating insulin resistance in liver. However, when we measured the plasma IL-1beta and IL-6 levels in SMLPL-/- mice, there was no indication that the circulating cytokine levels were elevated in the plasma of the mice.
###end p 67
###begin p 68
###xml 64 67 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 139 142 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 316 319 312 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 643 645 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 668 671 660 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 906 908 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 1011 1014 991 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 1015 1019 <span type="species:ncbi:10090">mice</span>
The downregulation of PPAR-gamma and SCD-1 in liver of the SMLPL-/- mice is consistent with the liver not storing excessive TG in the SMLPL-/- mice. SCD-1 catalyzes the desaturation of saturated fatty acyl-CoAs and is regulated by liver X receptor (LXR) (32). LXR gene expression, however, was not different in SMLPL-/- mice. SCD-1 has also been identified along with several other genes involved in lipogenesis as a direct target of PPAR-gamma in liver. Furthermore, SCD-1 plays a pivotal role in the regulation of hepatic and plasma lipoprotein TG concentrations, and SCD-1-deficient mice are usually protected against hypertriglyceridemia (33). Interestingly, SMLPL-/- mice had a borderline increase of plasma TG, despite the lower SCD-1 mRNA in liver. Moreover, PPAR-gamma is usually associated with greater liver TG storage, and hepatic overexpression of this transcription factor leads to steatosis (34). Given that both PPAR-gamma and SCD-1 mRNAs are lower and PGC-1alpha is higher in the livers of SMLPL-/- mice, the liver might respond to the excess delivery of FFAs by maintaining a higher rate of gluconeogenesis during insulin infusion in the clamp study.
###end p 68
###begin p 69
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
To summarize and conclude, the loss of SMLPL reduced skeletal muscle TG and increased insulin sensitivity. Despite the lack of change in whole-body insulin sensitivity at a young age, insulin resistance in WAT, liver, and heart was already evident. In the skeletal muscle of young SMLPL-/- mice, insulin signaling at the level of Akt was increased, suggesting that LPL-derived lipids influence both basal and insulin-stimulated Akt activation. Because the reduction of LPL-dependent lipid processing in skeletal muscle must result in the partitioning of TG-rich lipoproteins to other tissues, over time this promotes obesity development, a condition further enhanced by high-fat feeding.
###end p 69
###begin p 70
###xml 261 268 <span type="species:ncbi:4097">Tobacco</span>
This work was supported by grant NIDDK-26356 (to R.H.E.) and was partially supported by grant NIHDK-059767 (to J.E.F.); CO CNRU Core Grant NIH-P30DK048520; American Diabetes Association Grant 1-04-RA-47 (to J.K.K.); the Pennsylvania State Department of Health (Tobacco Settlement Award to J.K.K.); NIH R01: DK-40936, U24: DK-76169, and P30: DK-45735; and a Distinguished Clinical Scientist Award from the American Diabetes Association (all awards to G.I.S.).
###end p 70
###begin p 71
No potential conflicts of interest relevant to this article were reported.
###end p 71
###begin p 72
###xml 132 137 <span type="species:ncbi:10090">mouse</span>
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
The authors are grateful for the technical assistance from Jennifer Yoon in the laboratory of Dr. Eckel's group for ELISA assays of mouse plasma samples and mouse colony breeding and maintenance. We thank Pamila Allen at the Adult General Clinical Research Center at University of Colorado Denver for assistance with measuring mouse plasma lipids. We also thank Mario Kahn from the Department of Internal Medicine at Yale University School of Medicine for assistance in ceramide measurement.
###end p 72
###begin title 73
REFERENCES
###end title 73
###begin p 74
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 189 192 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 259 262 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 437 440 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 555 558 555 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 563 564 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 588 589 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 662 665 662 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 737 740 737 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 832 833 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 852 855 852 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 892 893 892 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 922 925 922 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 968 971 968 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1074 1075 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
A: mRNA expression of LPL in muscle tissues. LPL mRNA expression was measured in red skeletal muscle (SM-Red), white skeletal muscle (SM-White), and heart using RT-PCR. n = 3 for both SMLPL-/- and control mice. B: Tissue-specific LPL activities in young SMLPL-/- mice. Heparin-releasable LPL activities were measured for skeletal red muscle (SM-Red), skeletal white muscle (SM-White), WAT, and heart from both the 9- to 11-week-old SMLPL-/- and control mice. LPL activities were expressed as nanomoles of FFA per minute per gram of tissue. n = 8 for SMLPL-/- and n = 10 for control mice. C: Weight, lean mass, and fat mass comparisons between young and old SMLPL-/- mice. The body weights of young (8-9 weeks) and old (8-10 months) SMLPL-/- mice were compared. Body compositions were determined by dual-energy X-ray absorptiometry. n = 5 for both SMLPL-/- and control mice at different ages. D: Weight gain in HF-fed SMLPL-/- mice. The body weights of 6-week-old SMLPL-/- and control mice that are subjected to either HF or LF diet were monitored every 2 weeks for 6 weeks. n = 6 for each group of mice.
###end p 74
###begin p 75
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 306 309 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 378 379 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 483 484 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 529 530 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 544 547 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 549 550 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
Glucose tolerance test and insulin tolerance test of SMLPL-/- mice. Time courses of blood glucose levels in young SMLPL-/- and control mice after intraperitoneal injection of 1 g/kg glucose (A) or 0.75 units/kg insulin (B) are shown. Time courses are also shown of blood glucose levels in 6-month-old SMLPL-/- and control mice after intraperitoneal injection of 1 g/kg glucose (C) and for 12-week-old SMLPL-/- and control mice that have been subjected to different diet for 6 weeks (D). n = 6 for the glucose tolerance test, and n = 5 for SMLPL-/-; n = 4 for control mice in the insulin tolerance test.
###end p 75
###begin p 76
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 322 325 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 352 355 352 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 478 481 478 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 508 511 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 530 531 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 723 725 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 749 750 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 764 767 764 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 796 797 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 861 864 861 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 871 872 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 891 894 891 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 907 911 <span type="species:ncbi:10090">mice</span>
Whole-body insulin sensitivity and tissue-specific glucose uptake in vivo in the SMLPL-/- and control mice. A: Steady-state whole-body glucose infusion rate during hyperinsulinemic-euglycemic clamps and hepatic insulin action as the percent suppression of basal hepatic glucose production during the clamps for young SMLPL-/- mice. n = 5 for both SMLPL-/- and control mice. B: Steady-state whole-body glucose infusion rate during hyperinsulinemic-euglycemic clamps for old SMLPL-/- mice. n = 5 for both SMLPL-/- and control mice. C: Tissue-specific glucose uptake. Insulin-stimulated glucose uptake in skeletal muscle (gastrocnemius, SM), WAT, brown adipose tissue (BAT), and heart were measured by injecting a bolus of 2-[14C]-DG during the clamp. n = 5 for SMLPL-/- and n = 6 for control mice. D: Insulin-stimulated glucose transport in soleus muscle of SMLPL-/- mice (n = 3 for both SMLPL-/- and control mice). DPM, disintegrations per minute.
###end p 76
###begin p 77
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 179 182 179 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
Intracellular TG and lipid metabolite concentrations in skeletal muscle, liver, and heart. A: Intracellular TG concentrations in skeletal muscle, liver, and heart. n = 8 for SMLPL-/- and n = 10 for control mice for skeletal muscle, n = 4 for liver, and n = 6 for heart. B: Intracelluar LC acyl-CoA, DAG, and ceramides levels in skeletal muscle. n = 8 for both groups of mice.
###end p 77
###begin p 78
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 440 443 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 485 486 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 491 492 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 543 546 543 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 563 564 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 593 596 593 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
Insulin signaling in red skeletal muscle of the SMLPL-/- mice. Tryrosine phosphorylation levels of insulin receptor (A) and IRS-1 (B), PI 3-kinase activity (C), Ser473 phosphorylation level of Akt (D), and Thr308 phosphorylation level of Akt (E) were compared for the red skeletal muscle of both SMLPL-/- and control mice before and after insulin stimulation. Total SHIP2 and PTEN (F) were compared for the red skeletal muscle of both SMLPL-/- and control mice at basal condition. For A, B, D, and F, n = 4 for control mice and n = 5 for SMLPL-/- mice. For C and E, n = 3 for control and SMLPL-/- mice.
###end p 78
###begin p 79
###xml 183 186 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 315 318 315 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 361 362 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 376 379 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
Gene expression profiling in the skeletal muscle and liver of SMLPL mice. Expression levels of seven representative genes in red skeletal muscle were assessed by RT-PCR for both SMLPL-/- and control mice (A). n = 5 for both groups of mice. Expression levels of 13 representative genes in liver (B) of both the SMLPL-/- and control mice were assessed by RT-PCR. n = 6 for SMLPL-/- and n = 7 for control mice.
###end p 79
###begin p 80
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
General characterization of 9- to 11-week-old SMLPL-/- and control mice
###end p 80
###begin p 81
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
n = 8 for both groups of mice. MR, metabolic rate.
###end p 81
###begin p 82
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Plasma lipids, metabolites, and cytokines in 9- to 11-week-old SMLPL-/- and control mice
###end p 82
###begin p 83
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
n = 8 for glucose, insulin, and FFA measurement for both groups of mice. n = 6 for all other measurements.
###end p 83

